Related Experiment Video

Updated: Jun 17, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Antibody-maytansinoid conjugates for the treatment of myeloma

Robert J Lutz1, Kathleen R Whiteman

  • 1ImmunoGen, Inc., Waltham, MA, USA. Bob.lutz@immunogen.com

Mabs
|January 14, 2010
PubMed

Insights

New antibody-drug conjugates targeting CD56 and CD138 show promise for multiple myeloma treatment. These agents combine targeted antibody delivery with potent cytotoxic payloads to improve patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Multiple myeloma treatment requires novel therapeutic agents despite recent advances.
  • Monoclonal antibodies have shown success in cancer therapy, driving interest in antibody-based treatments for multiple myeloma.
  • Antibody-drug conjugates (ADCs) combine targeted antibody specificity with potent cytotoxic compounds.

Purpose of the Study:

  • To review preclinical and early clinical data for two novel antibody-based agents for multiple myeloma.
  • To highlight the potential of immunoconjugates targeting CD56 and CD138.

Main Methods:

  • Discussion of preclinical studies evaluating efficacy and safety.
  • Review of early-phase clinical trial data for IMGN901 and BT062.
  • Focus on antibody-maytansinoid conjugates targeting specific cell surface proteins.

Main Results:

  • IMGN901 targets CD56, expressed on most myeloma cells.
  • BT062 targets CD138, a key diagnostic marker for multiple myeloma.
  • Both agents utilize cytotoxic maytansinoids for anti-tumor activity.

Conclusions:

  • IMGN901 and BT062 represent promising new antibody-based therapies for multiple myeloma.
  • These immunoconjugates leverage targeted delivery for enhanced anti-myeloma activity.
  • Further clinical development is warranted to establish their therapeutic role.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...